A Phase 4 interventional study of Cetrorelix (Cetrotide) and Cetrorelix (Cetrotide) in Subfertility, sponsored by Aristotle University Of Thessaloniki. Completed at 1 site in Greece. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2009-11-01.
Sponsored by Aristotle University Of Thessaloniki · Phase 4, Interventional, and Treatment
This is a comparison of pregnancy achievement between two GnRH antagonist protocols which differ in the timing of GnRH antagonist initiation.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 146 is above the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Aristotle University Of Thessaloniki is the lead sponsor of 274 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Cetrorelix (Cetrotide)
Drug: Cetrorelix (Cetrotide)
flexible antagonist administration according to specified criteria
Also known as: Cetrorelix, Cetrotide, Serono
fixed antagonist administration on day 6 of ovarian stimulation
Also known as: Cetrorelix, Cetrotide, Serono
Luteinizing hormone rise
Time frame: 3-14 days (duration of ovarian stimulation)
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aristotle University Of Thessaloniki